MedTrace Logo

A Study of JNJ-69095897 in Healthy Participants

NCT04920578 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-69095897 versus placebo and to characterize the pharmacokinetic (PK) of JNJ-69095897 in blood, plasma, cerebrospinal fluid (CSF) and urine after single or divided oral dose administration in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

JNJ-69095897

JNJ-69095897 will be administered orally in Parts 1, 2 and 3.

OTHER

Placebo

Matching placebo will be administered orally in Parts 1 and 3.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Jannsen Research & Development, LLC Clinical Trial · Jannsen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2023-01-27
Completion
2023-02-27

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920578 on ClinicalTrials.gov